COR — Cencora, Inc.

As of 2026-08-27, sentiment is positive because Q3 FY26 revenue rose 5.1% to $84.75B, adjusted EPS of $4.48 beat and grew 12%, and management raised FY26 adjusted EPS guidance to $17.75-$17.95. Analysts are Buy-weighted (33 buy/12 hold/1 sell; consensus target $358.14), but price action has not turned bullish yet—the stock is below its 200-day SMA—so the bullish case still hinges on estimates and Q4 execution.

Revenue growth has downshifted from double-digit FY24/FY25 levels and stabilized around 5% YoY: Q3 FY26 revenue was +5.1%, up from +3.8% in Q2 FY26, with adjusted EPS growth of ~12%. Gross margin expanded to roughly 4.3% GAAP in Q3 FY26 from 3.3% in Q3 FY25 (the brief cites 61bps adjusted gross-margin expansion to 4.16%), helped by GLP-1 volumes and OneOncology. GAAP EPS is noisy—Q4 FY25 printed -$1.75 and Q2 FY26 printed $8.40, both one-off-driven—so use adjusted earnings and operating cash flow for trend read.

As of 2026-08-27, COR trades at 23.76x TTM GAAP EPS, but that overstates the cost because GAAP TTM includes one-off charges. On forward adjusted EPS of ~$17.88 (FY26 guidance midpoint/analyst average), the P/E is ~18.0x, below the 5-year average P/E of 24.4x. The stock is richer on sales (P/S 0.188x vs 5-yr avg 0.14x), and the deterministic score labels valuation 'Rich vs. its own history.' Overall: modestly expensive on sales, reasonable on forward earnings, and nowhere near a deep-value price.

At $321.23, the market is paying roughly 18x FY26 adjusted EPS. That is not pricing in much acceleration—it's paying a fair multiple for steady mid-single-digit top-line growth, ~12% adjusted EPS growth, and buybacks. If management delivers FY27 guidance in line with high-single-digit growth, current price has room to the high-300s; if margins mean-revert or GLP-1 volumes cool, the multiple could compress toward 15x, implying $270s. The supplied PEG of 0.62 is optically misleading; on ~12% growth, forward PEG is closer to 1.5.

As of 2026-08-27, RSI was 55.0 (neutral, not overbought/oversold). Price was +0.94% above its 20-day SMA and +5.0% above its 50-day SMA, but -0.53% below its 200-day SMA. That is a recovering, range-bound technical picture rather than a trend breakout. For entry timing, a decisive reclaim of the 200-day would be more constructive; a loss of the 50-day would negate the near-term recovery.

• GLP-1/weight-loss drug distribution volume remains a top-line accelerant; Q3 FY26 GLP-1 sales were $2.3B, up 25% YoY.
• Specialty/oncology services (OneOncology) and biosimilars are shifting mix from low-margin generics toward higher-margin, higher-touch distribution.
• Interest rates and carrying costs matter: long-term debt is ~$11.4B and net interest expense was $140.7M in Q3 FY26.
• FTC antitrust scrutiny—particularly the Covetrus-MWI Animal Health transaction—creates regulatory overhang for animal-health consolidation.
• Pharma distribution remains a high-volume, low-net-margin business (net margin ~0.8%), so contract renegotiations or payer changes have outsized EPS leverage.

• Q4/FY26 earnings (late Oct/early Nov 2026) and initial FY27 guidance, including confirmation of ~$3B FCF and buyback pace.
• FTC resolution on the Covetrus-MWI Animal Health transaction—clearance removes an overhang; a challenge would hurt.
• Continued execution on the $1B-per-quarter buyback pace and debt paydown, which supports EPS and reduces interest burden.
• Upside in GLP-1 or specialty oncology distribution volumes if new indications or supply expands.

• Extremely thin margins mean a modest miss in contract economics or customer consolidation can hit EPS hard.
• Leverage and working-capital needs: D/E is 3.84x and current ratio is 0.94; rising rates directly raise carrying costs.
• FTC/regulatory scrutiny could block or delay animal-health and oncology roll-up M&A, limiting the growth strategy.
• GLP-1 distribution growth is a major driver; reimbursement changes, supply-chain shifts, or manufacturer direct-to-pharmacy strategies could weaken volume.

Cencora is executing well: Q3 adjusted EPS grew 12%, FY26 guidance was raised, FCF is on track near $3B, and the buyback is chunky. But at $321.23 the stock is fairly valued on forward earnings and rich on sales, with high leverage and thin margins. I would not chase here; the risk/reward is balanced—hold for existing holders, look for a lower entry ($300 or below) or a positive Q4 guidance catalyst before adding.

Calculated by applying a 20x multiple to forward adjusted EPS of ~$17.88 (FY26 guidance midpoint/analyst average), justified by ~12% adjusted EPS growth, ROIC around 13%, and ~$3B FCF; 20x is a slight premium to the current ~18x forward multiple but below the 5-year average P/E of 24.4x.